Welcome to our dedicated page for Context Therapeutics SEC filings (Ticker: CNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Context Therapeutics Inc. (CNTX) SEC filings page on Stock Titan provides access to the company’s public regulatory documents, including current reports on Form 8-K and other filings made with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Context describes its business as a clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibodies for solid tumors, along with information on its capital markets activity and Nasdaq listing status.
Recent Forms 8-K furnished by Context include clinical and corporate updates tied to its TCE pipeline. For example, the company has reported Phase 1 dose-escalation progress for CTIM-76, a Claudin 6 x CD3 TCE in patients with ovarian, endometrial, or testicular cancer, and CT-95, a Mesothelin x CD3 TCE in patients with pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancers. Filings also describe CT-202, a Nectin-4 x CD3 TCE in preclinical development, and summarize safety observations, preliminary anti-tumor activity, and planned next steps as of the filing dates.
Other 8-Ks detail capital raising arrangements, such as an at-the-market Sales Agreement and its amendment, including aggregate offering limits, use of proceeds for research and development, working capital, and general corporate purposes, and the agent’s commission structure. Additional filings address Nasdaq minimum bid price notifications, extensions, and the company’s subsequent return to compliance, which are relevant for understanding listing risk and trading status.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify clinical trial disclosures, financing terms, and listing-related updates. Users can review new CNTX filings as they appear in EDGAR, then rely on AI-generated overviews to navigate complex regulatory language and focus on the sections most relevant to their analysis.